SpringWorks Therapeutics (SWTX) to Release Earnings on Thursday

SpringWorks Therapeutics (NASDAQ:SWTX) is expected to be releasing its earnings data before the market opens on Thursday, February 20th. Analysts expect SpringWorks Therapeutics to post earnings of ($0.66) per share and revenue of $60.53 million for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

SpringWorks Therapeutics (NASDAQ:SWTX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.03. The company had revenue of $49.10 million for the quarter, compared to analyst estimates of $53.28 million. SpringWorks Therapeutics had a negative net margin of 203.09% and a negative return on equity of 48.21%. The company’s revenue for the quarter was up 4810.0% on a year-over-year basis. During the same quarter last year, the firm earned ($1.27) EPS. On average, analysts expect SpringWorks Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

SpringWorks Therapeutics Price Performance

Shares of NASDAQ:SWTX opened at $57.43 on Friday. The company has a market capitalization of $4.27 billion, a price-to-earnings ratio of -14.80 and a beta of 0.81. The firm’s 50 day simple moving average is $39.03 and its 200 day simple moving average is $36.71. SpringWorks Therapeutics has a fifty-two week low of $28.21 and a fifty-two week high of $60.00.

Insiders Place Their Bets

In other SpringWorks Therapeutics news, Director Daniel Lynch sold 175,000 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $54.46, for a total value of $9,530,500.00. Following the transaction, the director now owns 130,944 shares of the company’s stock, valued at approximately $7,131,210.24. This represents a 57.20 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Badreddin Edris sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $41.97, for a total value of $839,400.00. Following the completion of the transaction, the chief operating officer now directly owns 209,600 shares in the company, valued at $8,796,912. This trade represents a 8.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 302,750 shares of company stock valued at $16,139,410 in the last ninety days. Company insiders own 7.61% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on SWTX shares. HC Wainwright reissued a “buy” rating and issued a $74.00 target price on shares of SpringWorks Therapeutics in a research note on Wednesday. Evercore ISI boosted their price target on SpringWorks Therapeutics from $60.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday. Guggenheim reduced their price target on SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Finally, Wedbush reiterated an “outperform” rating and issued a $77.00 target price on shares of SpringWorks Therapeutics in a report on Monday, February 10th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, SpringWorks Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $70.83.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.